COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

16/08/2024 - 22:14

Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic- [...]

Codexis Announces New Employment Inducement Grants

16/08/2024 - 22:05

REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the [...]

Theriva Biologics Announces Reverse Stock Split

16/08/2024 - 22:05

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, [...]

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16/08/2024 - 22:05

BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today [...]

Zealand Pharma major shareholder announcement: Bank of America Corporation

16/08/2024 - 18:05

Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), [...]

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

16/08/2024 - 16:55

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the [...]

Major shareholder announcement

16/08/2024 - 16:40

Please see the full announcement in PDF Attachments 2024_25_Major_Shareholders_Announcement Novozymes B 13 Aug 2024 Final Novozymes B 02 July 2024 Final Novozymes B 01 July 2024 Final Novozymes B 28 June 2024 Final [...]

Scorpius Holdings, Inc. Announces Pricing of Public Offering

16/08/2024 - 15:50

DURHAM, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced [...]

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

16/08/2024 - 15:01

Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of them Outcome further confirms Bentrio’s suitability for use by [...]

Genmab Announces Changes to its Executive Committee

16/08/2024 - 15:00

Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony [...]

Lighthouse Autism Center Partners with Local Government Officials to Highlight Autism Services and Community Impact

16/08/2024 - 15:00

MISHAWAKA, Ind., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Lighthouse Autism Center is excited to announce a series of visits from local government officials as part of Lighthouse’s community education initiative. Our mission [...]

Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

16/08/2024 - 15:00

MONTREAL, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (" Cannara " or the " Company ") ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis and derivative [...]

Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights

16/08/2024 - 14:30

- Q2 Revenues Increased 40% - Q2 Operating Expenses Decreased 17.7% - Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content - Revolutionary Formula to be Soon Released in Convenient 4-ounce Bottles [...]

HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services

16/08/2024 - 14:16

NAPLES, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. ( OTCQB: HLYK ), a leading provider of healthcare networking and technological innovation, has reported its financial results for the three- [...]

InnovAge PACE Celebrates Anniversary of Vibrant Sacramento Center

16/08/2024 - 14:00

PACE Program Provides Highly Coordinated Personalized Senior Care in Partnership with Eskaton and Adventist Health SACRAMENTO, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV [...]

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

16/08/2024 - 13:00

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16 th at 8:30 AM ET [...]

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16/08/2024 - 13:00

WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]

Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency

16/08/2024 - 13:00

World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1 Tonix’s live virus vaccine candidate, TNX-801, is designed to [...]

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

16/08/2024 - 13:00

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical [...]